A vs AVTR
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. AVTR: A global provider of mission-critical products and services for laboratory research and production workflows across biopharma and advanced industries.
Side-by-side fundamentals
| Metric | A | AVTR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $137.89 | $13.78 | |
| Market cap as of 2026-08-03 | $38.9B | $9.4B | |
| P/E as of 2026-08-03 | 27.64 | n/a | |
| PEG as of 2026-08-03 | 3.55 | n/a | |
| Net margin as of 2026-08-03 | +19.6% | -8.4% | A higher |
| Gross margin as of 2026-08-03 | +52.9% | +32.1% | A higher |
| Operating margin as of 2026-08-03 | +21.5% | -4.6% | A higher |
| ROE as of 2026-08-03 | +20.8% | -9.6% | A higher |
| ROA as of 2026-08-03 | +11.1% | -4.6% | A higher |
| Debt / equity as of 2026-08-03 | 0.47 | 0.68 | A lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.1% | -2.0% | A higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | -4.5% | A higher |
| Dividend yield as of 2026-08-03 | +0.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 1.24 | 0.98 | |
| 1-year return as of 2026-07-27 close | +14.7% | +2.5% | A higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.